BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Earnings

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and

Related news

IOVAIovance Biotherapeutics, Inc.2026-11-05 12:00 EST

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

SANASana Biotechnology2026-11-05 21:05 EST

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-11-05 12:00 EST

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-10-29 11:00 EST

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

IOVAIovance Biotherapeutics, Inc.2026-10-28 23:00 EST

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

IOVAIovance Biotherapeutics, Inc.2026-10-27 11:00 EST

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Stock data

Close
7.74 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States